Safety and efficacy of suture-mediated closure after percutaneous coronary interventions

被引:24
作者
Rinder, MR [1 ]
Tamirisa, PK [1 ]
Taniuchi, M [1 ]
Kurz, HI [1 ]
Mumm, K [1 ]
Lasala, JM [1 ]
机构
[1] Washington Univ, Sch Med, Div Cardiovasc, Dept Med, St Louis, MO 63110 USA
关键词
coronary artery disease; catheter-based interventions; closure devices; Perclose; complications; vascular access;
D O I
10.1002/ccd.1256
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Percutaneous coronary interventions (PCl) performed with concomitant use of heparin and platelet inhibitors are safe procedures with reported vascular complication rates of approximately 6.1%. EPILOG investigators demonstrated that utilizing a low-dose heparin regimen with abciximab, along with early sheath removal, vascular access-related bleeding was significantly lower than that reported in EPIC. Recently, a suture-mediated closure (SMC) device has been reported to be safe, appears effective, and may improve patient comfort by allowing early ambulation. We conducted a retrospective analysis (January 1999 to March 2000) of complication frequencies among PCI patients who underwent SMC and those who had manual compression (non-SMC). Furthermore, we compared the overall rates of complications to patients who underwent PCI prior to the introduction of SMC (1995-1998). When comparing the current cohort to the historical cohort, there was a significant decrease in the number of retroperitoneal bleeds (0.3% vs. 0.9%; P = 0.003), hematomas (5% vs. 9%; P < 0.001), pseudoaneurysms (1.2% vs. 2.7%; P < 0.001), and need for vascular surgery (0.9% vs. 2.8%; P < 0.001). There was no difference in the number of arterio-venous fistulas and a slight increase in transfusion needs (12% vs. 10%; P = 0.03). Within the current cohort, there was no difference in the vascular complications between SMC and non-SMC PCl patients, although there were lower rates of pseudoaneurysms (0.5% vs. 1.8%; P = 0.02) and transfusion requirements (72/880 vs. 132/874; P < 0.001). These results suggest that the complication rates for SMC are not different and may be lower when compared to non-SMC patients after PCl At our institution, the practice of early sheath removal and less aggressive heparin dosing has led to a decrease in vascular complication rates and a 66% reduction in vascular surgeries on post-PCl patients. Because of the limitations of retrospective analyses, further studies will be necessary to confirm these findings. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:146 / 151
页数:6
相关论文
共 11 条
[1]   Suture-mediated closure of the femoral access site after cardiac catheterization: Results of the suture to ambulate and discharge (STAND I and STAND II) trials [J].
Baim, DS ;
Knopf, WD ;
Hinohara, T ;
Schwarten, DE ;
Schatz, RA ;
Pinkerton, CA ;
Cutlip, DE ;
Fitzpatrick, M ;
Ho, KKL ;
Kuntz, RE .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (07) :864-869
[2]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[3]  
Carere RG, 1996, CATHETER CARDIO DIAG, V37, P367, DOI 10.1002/(SICI)1097-0304(199604)37:4<367::AID-CCD5>3.0.CO
[4]  
2-9
[5]  
Hanrath P, 1997, CIRCULATION, V96, P1445
[6]   Immediate post PTCA percutaneous suture of femoral arteries with the perclose device: Results of high volume users [J].
Morice, MC ;
Lefevre, T .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :101A-101A
[7]  
SIBER S, 1998, AM HEART J, V13, P152
[8]  
Tcheng JE, 1997, LANCET, V349, P1422
[9]   Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade [J].
Topol, EJ ;
Lincoff, AM ;
Califf, RM ;
Tcheng, JE ;
Kleiman, NS ;
Adelman, AG ;
Burton, JR ;
Talley, JD ;
Ivanhoe, RJ ;
Ducas, C ;
Cheung, PK ;
Schick, U ;
Badard, D ;
Kramer, J ;
Leary, J ;
Snyder, H ;
Wilson, R ;
Dearen, M ;
Caramori, P ;
Webber, S ;
Taylor, J ;
Ferrando, T ;
Cohen, E ;
Balleza, L ;
Rouse, C ;
Hogg, N ;
Kelly, T ;
Alston, S ;
Webb, J ;
Buller, E ;
Ricci, DR ;
Mockman, S ;
Tanguay, JF ;
Poitras, AM ;
Timis, G ;
Davey, D ;
Coleman, P ;
Herrold-Runge, P ;
O'Neill, BJ ;
Foshey, K ;
Fitzgerald, N ;
Almond, D ;
Kostuk, W ;
White, J ;
Oskalns, R ;
Gottlieb, R ;
Koren, P ;
Palazzo, D ;
Azrin, M ;
Barry, MB .
LANCET, 1998, 352 (9122) :87-92
[10]  
Topol EJ, 1997, NEW ENGL J MED, V336, P1689